Literature DB >> 19616694

Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry.

Hao Wu1, Ruyi Xue, Ling Dong, Taotao Liu, Chunhui Deng, Huazong Zeng, Xizhong Shen.   

Abstract

With the technique of metabolomics, gas chromatography/mass spectrometry (GC/MS), urine or serum metabolites can be assayed to explore disease biomarkers. In this work, we present a metabolomic method to investigate the urinary metabolic difference between hepatocellular carcinoma (HCC, n - 20) male patients and normal male subjects (n - 20). The urinary endogenous metabolome was assayed using chemical derivatization followed by GC/MS. After GC/MS analysis, 103 metabolites were detected, of which 66 were annotated as known compounds. By a two sample t-test statistics with p < 0.05, 18 metabolites were shown to be significantly different between the HCC and control groups. A diagnostic model was constructed with a combination of 18 marker metabolites or together with alphafetoprotein, using principal component analysis and receiver-operator characteristic curves. The multivariate statistics of the diagnostic model yielded a separation between the two groups with an area under the curve value of 0.9275. This non-invasive technique of identifying HCC biomarkers from urine may have clinical utility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616694     DOI: 10.1016/j.aca.2009.06.033

Source DB:  PubMed          Journal:  Anal Chim Acta        ISSN: 0003-2670            Impact factor:   6.558


  50 in total

1.  Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.

Authors:  Tianlu Chen; Guoxiang Xie; Xiaoying Wang; Jia Fan; Yunping Qiu; Xiaojiao Zheng; Xin Qi; Yu Cao; Mingming Su; Xiaoyan Wang; Lisa X Xu; Yun Yen; Ping Liu; Wei Jia
Journal:  Mol Cell Proteomics       Date:  2011-04-25       Impact factor: 5.911

Review 2.  Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry.

Authors:  Masaru Yoshida; Naoya Hatano; Shin Nishiumi; Yasuhiro Irino; Yoshihiro Izumi; Tadaomi Takenawa; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2011-11-02       Impact factor: 7.527

3.  Can proteomics lead to the discovery of real biomarkers for HCC?

Authors:  Yasuhiro Kuramitsu
Journal:  World J Hepatol       Date:  2010-02-27

4.  Differential Mobility Spectrometry-Mass Spectrometry (DMS-MS) in Radiation Biodosimetry: Rapid and High-Throughput Quantitation of Multiple Radiation Biomarkers in Nonhuman Primate Urine.

Authors:  Zhidan Chen; Stephen L Coy; Evan L Pannkuk; Evagelia C Laiakis; Albert J Fornace; Paul Vouros
Journal:  J Am Soc Mass Spectrom       Date:  2018-05-07       Impact factor: 3.109

Review 5.  Review of mass spectrometry-based metabolomics in cancer research.

Authors:  David B Liesenfeld; Nina Habermann; Robert W Owen; Augustin Scalbert; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-04       Impact factor: 4.254

Review 6.  Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.

Authors:  Shreya Sengupta; Neehar D Parikh
Journal:  Hepat Oncol       Date:  2017-11-17

7.  Comparative analysis of creatinine and osmolality as urine normalization strategies in targeted metabolomics for the differential diagnosis of asthma and COPD.

Authors:  Mona M Khamis; Teagan Holt; Hanan Awad; Anas El-Aneed; Darryl J Adamko
Journal:  Metabolomics       Date:  2018-08-29       Impact factor: 4.290

8.  Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma.

Authors:  Shu-Ye Liu; Rikki-Lei Zhang; Hua Kang; Zhi-Juan Fan; Zhi Du
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

9.  Metabolomic analysis of human disease and its application to the eye.

Authors:  Stephen P Young; Graham R Wallace
Journal:  J Ocul Biol Dis Infor       Date:  2009-11-13

Review 10.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.